Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy and lacks effective therapeutic targets. Trametinib is considered to be a promising potential indirectly targeted KRAS inhibitor in PDAC. However, the clinical outcomes were poor. JQ1 displayed a significant synergistic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaofei, Mao, Tiebo, Xu, Haiyan, Li, Shumin, Yue, Ming, Ma, Jingyu, Yao, Jiayu, Wang, Yongchao, Zhang, Xiao, Ge, Weiyu, Wang, Yanling, Shentu, Daiyuan, Wang, Liwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085242/
https://www.ncbi.nlm.nih.gov/pubmed/35468095
http://dx.doi.org/10.18632/aging.204031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085242/
https://www.ncbi.nlm.nih.gov/pubmed/35468095
http://dx.doi.org/10.18632/aging.204031

Ejemplares similares